MiniMed Group, Inc. (MMED)
| Market Cap | 5.06B |
| Revenue (ttm) | 3.22B +15.7% |
| Net Income | -314.00M |
| EPS | -1.19 |
| Shares Out | 281.35M |
| PE Ratio | n/a |
| Forward PE | 29.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,376,894 |
| Open | 17.92 |
| Previous Close | 17.88 |
| Day's Range | 17.65 - 18.15 |
| 52-Week Range | 10.65 - 24.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.33 (+40.8%) |
| Earnings Date | Nov 24, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$333.00 million, 56.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for MMED stock is "Buy." The 12-month stock price target is $25.33, which is an increase of 40.80% from the latest price.
News
MiniMed price target lowered to $20 from $22 at Barclays
Barclays lowered the firm’s price target on MiniMed (MMED) to $20 from $22 and keeps an Equal Weight rating on the shares.
MiniMed to Participate in Upcoming Investor Conferences
NORTHRIDGE, Calif., Nov. 5, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Chad Spooner, EVP, Chief Financial Officer, will discuss and answe...
MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results
NORTHRIDGE, Calif., Nov. 4, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, November 24, 20...
MiniMed appoints David Segal as Chief Medical Officer
MiniMed (MMED) appointed David Segal as Chief Medical Officer. Segal succeeds Robert Vigersky, who will transition to the role of Chief Medical Officer Emeritus ahead of his planned retirement at…
MiniMed Appoints Dr. David Segal as Chief Medical Officer
NORTHRIDGE, Calif., Nov. 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the appointment of David Segal, M.D.
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused ...
Medtronic Completes Separation of MiniMed Group, Inc.
GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). "I'm incredibly pro...
MiniMed Completes Separation from Medtronic
NORTHRIDGE, Calif., Oct. 15, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc ("Medtronic"; NYSE: MDT), marking its first day as a fully ...
Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
GALWAY, Ireland, Oct. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final results of its previously announced offer to exchange shares of common stock of MiniMed Gr...
MiniMed initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of MiniMed (MMED) with a Buy rating and $30 price target The firm says that with a “meaningfully improved” product offering, including new pump…
Medtronic says MiniMed exchange offer oversubscribed
Medtronic (MDT) announced that, based on preliminary results, its previously announced offer to exchange shares of common stock of MiniMed Group (MMED) for outstanding Medtronic ordinary shares was ov...
Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer
GALWAY, Ireland, Oct. 12, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that, based on preliminary results, its previously announced offer to exchange shares of common stoc...
MiniMed initiated with a Hold at Jefferies
Jefferies initiated coverage of MiniMed (MMED) with a Hold rating and $22 price target While the company’s performance and competitive position have improved, channel checks suggests its new products ...
MiniMed Group Transcript: AGM 2026
All four proposals passed preliminarily, including the Class I director elections and a one-year frequency for future say-on-pay votes. Final results were due in an SEC filing within four business days.
MiniMed price target raised to $28 from $26 at Mizuho
Mizuho raised the firm’s price target on MiniMed (MMED) to $28 from $26 and keeps an Outperform rating on the shares. The implied negative 3% Medtronic exchange offer on top…
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.
GALWAY, Ireland, Oct. 7, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinar...
MiniMed initiated with an Equal Weight at Barclays
Barclays initiated coverage of MiniMed (MMED) with an Equal Weight rating and $22 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
MiniMed reports clinical evidence on MiniMed Smart MDI system usage
MiniMed (MMED) presented new clinical evidence showing that people with type 1 diabetes using the MiniMed Smart MDI system who responded to more missed-dose and high-glucose alerts had, on average,…
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
Six-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders. NORTHRIDGE, Calif.
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
MiniMed names Sheila Denton as General Counsel & Corporate Secretary
MiniMed (MMED) announced that Sheila Denton has been named General Counsel & Corporate Secretary. Denton brings broad-ranging expertise in corporate governance, strategic transactions, intellectual pr...
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secreta...
MiniMed initiated with a Buy at Truist
Truist initiated coverage of MiniMed (MMED) with a Buy rating and $29 price target The company is near the final stage of its split-off from Medtronic (MDT), trading close to…
MiniMed Group Transcript: Bank of America Global Healthcare Conference
The company is accelerating growth with a robust innovation pipeline, including new launches like Flex and Fit, and a differentiated closed-loop algorithm, Vivera, targeting a 2027 launch. Strong commercial scale, disciplined financial management, and a stable, incentivized team underpin durable growth and expanding global presence.
MiniMed files S-4 in connection with Medtronic exchange offer
MiniMed (MMED) announced that it has filed a Form S-4 Registration Statement with the SEC in connection with Medtronic’s (MDT) offer to exchange up to 225,361,295 shares of MiniMed common…